MedTrace Logo

Safety and Efficacy of AIN457 in Noninfectious Uveitis

NCT00685399 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2017-07-17

Study results available
· View outcomes & findings →

Summary

This study was performed to evaluate the efficacy and safety of AIN457 for patients with active uveitis that requires systemic immunosuppression.

Conditions

  • Non-infectious Uveitis

Interventions

DRUG

AIN457

AIN457 subcutaneous dose

DRUG

AIN 457

AIN457 low dose (i.v)

DRUG

AIN457

AIN457 high dose (i.v)

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2013-09-30
Completion
2013-09-30

Countries

  • United States
  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00685399 on ClinicalTrials.gov